Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
British Journal of Cancer
|
December 22, 2011
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
L Khoja, A Backen, R Sloane, et al.
Cell Death & Disease
|
April 6, 2026
The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer
J Searle, M Menotti, W J McDaid, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2000
p53 and related proteins in epithelial ovarian cancer
P S Sengupta, A T McGown, V Bajaj, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 26, 2019
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial
R Y Tay, F Fernández-Gutiérrez, V Foy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2010
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
P Wheatley-Price, F Blackhall, S-M Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 3, 2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
M Früh, C M Panje, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
G V Scagliotti, I Bondarenko, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer
J-C Soria, S N Ho, M Varella-Garcia, et al.
Molecular Cancer
|
November 13, 2024
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS<sup>G12D</sup>-driven non-small cell lung cancer
W J McDaid, L Wilson, H Adderley, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 17, 2024
Patient Experiences of Using Wearable Health Monitors During Cancer Treatment: A Qualitative Study
S Collinson, S Ingram-Walpole, C Jackson, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
British Journal of Cancer
|
December 22, 2011
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
L Khoja, A Backen, R Sloane, et al.
Cell Death & Disease
|
April 6, 2026
The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer
J Searle, M Menotti, W J McDaid, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2000
p53 and related proteins in epithelial ovarian cancer
P S Sengupta, A T McGown, V Bajaj, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 26, 2019
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial
R Y Tay, F Fernández-Gutiérrez, V Foy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2010
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
P Wheatley-Price, F Blackhall, S-M Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 3, 2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
M Früh, C M Panje, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
G V Scagliotti, I Bondarenko, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer
J-C Soria, S N Ho, M Varella-Garcia, et al.
Molecular Cancer
|
November 13, 2024
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS<sup>G12D</sup>-driven non-small cell lung cancer
W J McDaid, L Wilson, H Adderley, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 17, 2024
Patient Experiences of Using Wearable Health Monitors During Cancer Treatment: A Qualitative Study
S Collinson, S Ingram-Walpole, C Jackson, et al.
Page
of 4